RxDoctor Payments Data

Michael Ryan, APRN

Family · San Antonio, TXNPI 1235571910

Payments from drug & device makers

$1,953in general payments, 2019–2025

Across 19 payments — averaging $102.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$247
  • Novo Nordisk$178
  • Silk Road Medical, Inc.$143
  • Boston Scientific$142
  • AstraZeneca$120
  • Biohaven Pharmaceutical Holding Company Ltd.$120
  • plus $1K from 11 others

What the payments were for

  • Food & beverage$1,953100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,953 in reported general payments places this provider in the 80th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$20,730
Medicare patients
143
Services billed
439

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide97$104,265
MounjaroTirzepatide41$57,696
EliquisApixaban47$44,390
Bydureon BciseExenatide Microspheres16$30,907
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$25,601
JardianceEmpagliflozin15$22,824
XareltoRivaroxaban14$21,601
TrulicityDulaglutide11$21,403
JanuviaSitagliptin Phosphate13$17,841
Gabapentin175$4,029
Lantus SolostarInsulin Glargine,hum.Rec.Anlog32$3,909
Omeprazole109$2,929
Atorvastatin Calcium293$2,504
Levothyroxine Sodium227$1,637
Albuterol Sulfate HfaAlbuterol Sulfate60$1,582

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$178$104,26597 claims
Boehringer IngelheimJardiance$98$22,82415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 15,456 family providers in Texas.

Other family in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →